A differentiated way to generate real-world evidence in neuropsychiatry
Osmind actively supports sponsors ranging from top 5 pharma to clinical stage biotechs to neurotechnology companies.
Our projects have included retrospective analyses, prospective data capture, data-driven trials recruitment, and market research for use cases spanning translational research, clinical development, medical affairs, and commercial.
"Working with Osmind was the first time my RWE group used EHR data. We had looked in the past but couldn't find any other EHR data with deep outcomes data. Our project with Osmind was very successful, with a combination of strong RWD and impressive analytic outputs all delivered ahead of schedule. The results are making a big impact internally and externally with payers and HCPs."
“Our collaboration with Osmind offers promise to broaden the scope of our impact on psychiatry and on the patients we serve.”
“Real-world evidence data collection is taking off in the ketamine space, and it's clear Osmind are field leaders here. I look forward to seeing real-world evidence initiatives being utilized when MDMA and psilocybin therapy become available for patients. It will be essential for assessing their relative merits versus already existing treatment options, including ketamine infusion therapy.”
“Osmind’s approach to unlocking next-generation treatments by leveraging real-world evidence and their digital infrastructure has the potential to meaningfully impact our ability to bring new treatments to patients in dire need. They’ve made incredible progress already.”
Connecting the point-of-care with life sciences innovation
Our software is the
system of record
Our fully-integrated software platform includes an EHR, patient app, practice management system, clinician community, and advanced analytics system
Depth and quality of real-world data
High quality clinical and outcomes data at scale. Structured for research from the point of data generation, e.g. from our library of 40+ outcomes measures
Direct relationship
with clinics
Network of engaged, research-forward clinicians using our software and in our proprietary clinician community
Direct relationship
with patients
Network of engaged patients actively using our software
Accelerate your programs across the development lifecycle
Trusted by leading companies. Below are examples from recent
projects we have conducted.
Translational research
Example: We used RWD to develop novel subtypes of psychiatric conditions for more precise therapeutic targeting
Clinical development
Example: We used RWD to help design clinical trials and recruit patients for studies
Medical affairs
Example: We assessed the real-world effectiveness and treatment patterns of novel psychiatric therapies and produced high-impact publications geared towards HCPs and payers
Commercial
Example: We conducted market research studies to understand clinician perspectives, educated clinicians about new treatments, and helped them adjust their workflows accordingly (e.g. with the automation of REMS)
What we do
- Retrospective analyses of RWD
- Prospective data capture for RWE generation
- Data-driven trials recruitment
- Market research (combination of qualitative and quantitative including linkage with RWD)
Featured news & research
Comparative Effectiveness of Ketamine Intravenous Therapy and Intranasal Esketamine for Depression in Real-world Settings
McInnes and Kane (2024). American Society of Clinical Psychopharmacology Annual Meeting.
A retrospective study of real-world outcomes for esketamine nasal spray among patients with treatment resistant depression
McInnes, Joshi, Kane, et al. (2024). American Society of Clinical Psychopharmacology Annual Meeting.
Impact of duration of esketamine nasal spray treatment on change in depression symptoms in real-world patients
McInnes, Joshi, Kane, et al. (2024). American Society of Clinical Psychopharmacology Annual Meeting.
Measurement Based Care Learning Lab
MacMillan (2024). American Psychiatric Association Annual Meeting.
Psychiatric Treatments that have FDA’s Breakthrough Therapy Status
MacMillan (2024). American Psychiatric Association Annual Meeting.
Osmind Announces Collaboration with the American Psychiatric Association to Advance Quality Psychiatric Care and Accelerate Research
Osmind Announces Collaboration with the American Psychiatric Association to Advance Quality Psychiatric Care and Accelerate Research
Osmind Announces 2024 Community Advisory Board: Leading Mental Health Clinicians
Osmind Announces 2023 Community Advisory Board: Leading Mental Health Clinicians
Comparative Effectiveness of Ketamine Intravenous Therapy and Intranasal Esketamine for Depression in Real-world Settings
McInnes and Kane (2024). American Society of Clinical Psychopharmacology Annual Meeting.
A retrospective study of real-world outcomes for esketamine nasal spray among patients with treatment resistant depression
McInnes, Joshi, Kane, et al. (2024). American Society of Clinical Psychopharmacology Annual Meeting.
Impact of duration of esketamine nasal spray treatment on change in depression symptoms in real-world patients
McInnes, Joshi, Kane, et al. (2024). American Society of Clinical Psychopharmacology Annual Meeting.
Measurement Based Care Learning Lab
MacMillan (2024). American Psychiatric Association Annual Meeting.
Psychiatric Treatments that have FDA’s Breakthrough Therapy Status
MacMillan (2024). American Psychiatric Association Annual Meeting.
A phase 2 trial with CLE-100 oral esketamine for patients with MDD and inadequate response to antidepressant during COVID-19 pandemic
Hagai et al. (2024). Oxford Ketamine Conference.
